Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
HAYWARD, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (“Anthera” or the “Company”) announced today that it has withdrawn its request for a hearing to...
Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”)Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”)Further...
HAYWARD, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat...
HAYWARD, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that Anthera has received formal notice from The NASDAQ Stock Market LLC (“Nasdaq”...
RESULT study reported positive interim futility analyses and completion of dosing, with top line data expected in March 2018Completed private placement for net proceeds of $13.3 million...
HAYWARD, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat...
HAYWARD, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) is pleased to announce that the final patient has completed the last visit in the primary...
HAYWARD, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that on January 24, 2018, Anthera received formal notice that the Nasdaq...
HAYWARD, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for...
HAYWARD, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has completed the second closing of the private placement of its equity...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 1440 | 1.0E-6 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 1870 | 1.0E-6 | CS |
| 12 | -9.9E-5 | -99 | 0.0001 | 0.0002 | 1.0E-6 | 16467 | 4.389E-5 | CS |
| 26 | 0 | 0 | 1.0E-6 | 0.0002 | 1.0E-6 | 15237 | 7.105E-5 | CS |
| 52 | 0 | 0 | 1.0E-6 | 0.0002 | 1.0E-6 | 13158 | 6.667E-5 | CS |
| 156 | 0 | 0 | 1.0E-6 | 0.008 | 1.0E-6 | 14868 | 8.686E-5 | CS |
| 260 | -0.038899 | -99.9974293059 | 0.0389 | 0.189 | 1.0E-6 | 88687 | 0.04109276 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
